The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
Abstract Background Although immune modulation is a promising therapeutic avenue in coronavirus disease 2019 (COVID-19), the most relevant targets remain to be found. COVID-19 has peculiar characteristics and outcomes, suggesting a unique immunopathogenesis. Methods Thirty-six immunocompetent non-CO...
Main Authors: | Mathieu Blot, Jean-Baptiste Bour, Jean Pierre Quenot, Abderrahmane Bourredjem, Maxime Nguyen, Julien Guy, Serge Monier, Marjolaine Georges, Audrey Large, Auguste Dargent, Alexandre Guilhem, Suzanne Mouries-Martin, Jeremy Barben, Belaid Bouhemad, Pierre-Emmanuel Charles, Pascal Chavanet, Christine Binquet, Lionel Piroth, for the LYMPHONIE study group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-020-02646-9 |
Similar Items
-
Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
by: Mathieu Blot, et al.
Published: (2021-03-01) -
Specific Features of the Coagulopathy Signature in Severe COVID-19 Pneumonia
by: Mathieu Blot, et al.
Published: (2021-08-01) -
Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study
by: Georg Pilz, et al.
Published: (2019-01-01) -
The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF
by: Christine Harrer, et al.
Published: (2021-08-01) -
Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
by: Georg Pilz, et al.
Published: (2020-02-01)